Nabsys Electronic Genome Mapping Advances Cancer Analysis
Providence, Rhode Island, USA, September 17, 2026 Nabsys, Inc. has announced the publication of research from Augusta University demonstrating...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Providence, Rhode Island, USA, September 17, 2026 Nabsys, Inc. has announced the publication of research from Augusta University demonstrating...
PROVIDENCE, R.I., July 31, 2026 Nabsys 2.0, LLC has entered into a multi-year research collaboration with Indiana University School...
CARLSBAD, Calif., June 11, 2026 Arima Genomics, a cancer diagnostics company focused on integrating DNA sequence and genome structure...
San Diego, California – May 17, 2026 Nabsys 2.0 announced the expansion of its OhmX™ electronic genome mapping (EGM)...
February 25, 2026 – San Diego, California, USA Bionano Genomics highlighted major scientific advancements in Optical Genome Mapping (OGM)...
